Chronic Myeloid Leukemia Coverage from Every Angle
Advertisement
Advertisement

François-Xavier Mahon, MD, PhD, on When to Stop Second-Line Nilotinib in Chronic-Phase Chronic Myeloid Leukemia

Posted: Sunday, June 2, 2019

François-Xavier Mahon, MD, PhD, of the Université Bordeaux and Institut Bergonie, discusses the clinical relevance of the long-term results from the ENESTop trial, which studied halting treatment after second-line nilotinib in chronic-phase CML.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.